CSL Limited는 주당 2.7577의 연간 배당금을 지급하며, 수익률은 0.00%입니다. 배당금은 반기별에 지급되며, 마지막 배당금 지급일은 Sep 9, 2025였습니다.
배당수익률
연간 배당금
배당금 지급일 전일
0.00%
$2.7577
Sep 9, 2025
지급 빈도
지급 비율
반기별
0.00%
배당금 이력
배당금 지급일 전일
현금 금액
기록 일자
지급일
Sep 9, 2025
$2.4508
Sep 10, 2025
Oct 3, 2025
Mar 10, 2025
$2.0711
Mar 11, 2025
Apr 9, 2025
Sep 9, 2024
$2.1746
Sep 10, 2024
Oct 2, 2024
Mar 11, 2024
$1.7989
Mar 12, 2024
Apr 3, 2024
Sep 11, 2023
$2.0938
Sep 12, 2023
Oct 4, 2023
Mar 9, 2023
$1.6215
Mar 10, 2023
Apr 5, 2023
배당금 차트
CMXHF 배당금
CMXHF 배당금 성장률(년간 비교)
주요 통계
이전 종가
$111.43
시가
$103.23
일일 범위
$102.45 - $110.47
52주 범위
$102.45 - $184.09
거래량
21
평균 거래량
3.2K
EPS(TTM)
6.17
배당수익률
--
시가총액
$49.7B
CSL LTD란 무엇인가요?
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. The company is headquartered in Melbourne, Victoria and currently employs 32,065 full-time employees. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The firm operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.